Horizon Pharma Buys Raptor

by | Sep 16, 2016 8:31 am | Pharmaceuticals

For the week ending September 16, 2016, a combined $1.01 billion was spent on three pharmaceutical deals, one of which is also the largest pharmaceutical deal so far in September. Horizon Pharma plc (NASDAQ: HZNP), which develops, acquires and commercializes medicines for the treatment of arthritis, pain, inflammatory and/or orphan diseases, acquired Raptor Pharmaceuticals Corp. (NASDAQ: RPTP) for approximately $800 million, or $9.00 per share. Raptor focuses on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The transaction gives Horizon global rights to PROCYSBI® delayed-release capsules, used to treat nephropathic... Read More »